Introduction: The human breast secretes three types of milk during lactation - colostrum, transitional milk and mature milk However, like any other biofluid, human breast milk is not pristine. Objectives: The objectives of this study was to determine the levels of polychlorinated biphenyls congeners in colostrum, transitional milk and mature milk of mothers at the Ho Teaching Hospital to ascertain which portion contained the highest levels of PCPBs that could pose any significant health risks to neonates. Methodology: A cross-sectional study design was employed to conduct the study at the Ho Teaching Hospital. Protocol for the study was reviewed and approved by the University of Health and Allied Sciences Research Ethics Committee (UHAS-REC). The study recruited forty-seven (47) mothers using purposive sampling. About 10.0 g of each aliquot of colostrum, transitional milk and mature milk were treated using a modified form of QuEChERS to extract PCBs and the resulting extract analyzed for fourteen (14) PCB congeners using GC/MS/MS. Results: Fourteen (14) PCB congeners were examined in all the 141 breast samples, which represented three different types of human milk. All samples had levels that were below thresholds of detection. The lack of PCB residues in the examined samples may be viewed as positive news. It might suggest that the mothers were only minimally exposed to these industrial pollutants. Conclusion: At any stage of lactation, no PCBs were found in the breast milk samples. As a result, there were no obvious health concerns for breastfed infants from the levels of PCBs found in the samples of breast milk that were examined. The result is good news for international efforts to eliminate PCBs in the environment and on people.

The authors have declared no competing interest.

The study was funded be the University of Health and Allied Sciences Research Fund And Ghana Standards Authority

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

University of Health and Allied Sciences Research Committee (UHAS - REC), Protocol Number: UHAS-REC A.9 (6) 20-21

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the study are available upon request.